Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research> UBS Lowers TP of CHINA BIOPHARMACEUTICAL (01177.HK) to HKD11, Rating 'Buy'
Recommend 4 Positive 9 Negative 4 |
||||
|
||||
|
UBS released a research report stating that CHINA BIOPHARMACEUTICAL (01177.HK) recorded a revenue of RMB31.8 billion last year, representing a year-on-year increase of 10.3%, which was below expectations. The net profit reached RMB2.3 billion, up 22% year-on-year, also below expectations. The gross profit margin increased by 0.6 percentage points year-on-year to 82.1%. The management expects that driven by the continuous growth of innovative products, this year's revenue and profit will achieve double-digit growth. The firm raised the EPS forecast for CHINA BIOPHARMACEUTICAL for this year by 9.4%. However, due to lower expected revenue and profitability from generic drugs, it lowered the EPS forecasts for 2027 and 2028. Additionally, the company's target price was reduced from HKD12.2 to HKD11, reaffirming the 'Buy' rating. (ca/j) Auto-translated by third-party software This translation was auto-generated by third-party software. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
URL: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
